Ciclesonide a challenge to the best of asthma therapies

    loading  Checking for direct PDF access through Ovid

Abstract

Inhaled ciclesonide [Alvesco] is as effective as oral prednisolone in patients with an acute asthma exacerbation, according to data presented at the 102nd International Conference of the American Thoracic Society (ATS) [San Diego, California, US; May 2006], which featured ciclesonide as the topic of several comparative trials. Going head-to-head with fluticasone propionate, beclometasone and budesonide, ciclesonide was shown to be at least as effective as all three individual therapies. Furthermore, ciclesonide demonstrated a favourable tolerability profile over fluticasone with respect to local oropharyngeal events, and over both prednisolone and budesonide with respect to the impact on the hypothalamic-pituitary-adrenal (HPA) axis.

Related Topics

    loading  Loading Related Articles